Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03779243 · ClinicalTrials.gov registry record · NA
Treatment for Sleep Disturbance in Orthopaedic Trauma Patients
A NA study of Trauma and Sleep Disturbance, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT03779243: Completed NA study of Trauma and Sleep Disturbance, sponsored by Stanford University.
NCT03779243 is a NA study of Trauma and Sleep Disturbance that has completed, run by Stanford University. The registered enrollment target is 90 participants, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03779243, a NA study of Trauma and Sleep Disturbance, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test the efficacy of sleep treatment in human patients following traumatic injury. Specifically, the study will determine if treatment consisting of melatonin and education related to sleep habits are effective in treating sleep disturbance and improving sleep quality in Orthopaedic trauma patients. We hope to learn if melatonin and sleep education effectively improve sleep following traumatic injury, and improve outcomes.
Primary Outcome
9-item self-rated questionnaire that assesses clinical sleep quality and disturbances. Global PSQI scores are sums of the component scores, and range from 0-21. Higher scores indicate worse sleep quality.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Melatonin 5mg and Sleep Education
Study Locations (1)
California
- Stanford - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2021-08-24 |
| Phase | NA |
What the finished NCT03779243 record still lists
NCT03779243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Trauma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03779243 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03779243 about?
NCT03779243 is a clinical study titled "Treatment for Sleep Disturbance in Orthopaedic Trauma Patients". The purpose of the study is to test the efficacy of sleep treatment in human patients following traumatic injury. Specifically, the study will determine if treatment consisting of melatonin and education related to sleep habits are effective in treating sleep disturbance and improving sleep quality ...
What is the current status of trial NCT03779243?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2019-01-07. Estimated completion is 2021-08-24.
What conditions does trial NCT03779243 study?
This clinical trial studies the following conditions: Trauma, Sleep Disturbance.
What interventions are being tested in trial NCT03779243?
The interventions under investigation include: Placebo (OTHER), Melatonin 5mg and Sleep Education (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03779243?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03779243 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trauma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03779243's enrollment target sits among peer trials
90 33rd of 56 higher than 24 of 56 other Trauma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Trauma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing FIRST in Youth Outpatient Psychotherapy
RECRUITING · NA
-
PRESERVE & CONNECT: Impact Study of the BPC
RECRUITING · NA
-
Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)
RECRUITING · NA
-
Evaluation of the Parenting in the Moment Online Program for Forcibly Displaced Families
RECRUITING · NA
-
RCT: Early Feeding After PEG Placement
RECRUITING · NA
-
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI